High dose cabergoline in management of ovarian hyperstimulation syndrome.
OBJECTIVE
To describe a case of moderate ovarian hyperstimulation syndrome (OHSS) that was treated with high dose cabergoline.


METHODS
Case report.


METHODS
Private assisted reproduction center.


METHODS
A 29-year-old woman who developed early moderate OHSS despite preventive cabergoline administration (0.5 mg/day) following controlled ovarian hyperstimulation for IVF treatment.


METHODS
Cabergoline dose was increased to 1 mg/day upon diagnosis of OHSS on the second day after oocyte collection and embryo transfer was postponed to the fifth day after oocyte collection.


METHODS
Resolution of OHSS and achievement of healthy live birth.


RESULTS
OHSS resolved rapidly despite occurrence of pregnancy and patient delivered a healthy boy at term.


CONCLUSIONS
The higher cabergoline dose might have prevented an increase in the severity of OHSS and its prolongation following occurrence of pregnancy. Randomized controlled trials assessing the efficacy and safety of different doses and durations of cabergoline administration in both prophylactic and therapeutic settings are required.
Ata
Baris
B
American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey; Soranus IVF Center, Bursa, Turkey. Electronic address: barisata@hotmail.com.
Seyhan
Ayse
A
American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey.
Orhaner
Serbulent
S
Soranus IVF Center, Bursa, Turkey.
Urman
Bulent
B
American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey.
D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000188:drug therapy* / Q000517:prevention & control; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline